The "Electrodiagnostic Medicine Patient Protection and Fraud Elimination Act of 2025" seeks to enhance patient safety and combat fraud within the Medicare program's electrodiagnostic services. This legislation mandates that, after a specified period, Medicare will only provide payment for nerve conduction studies and needle electromyography tests if they are furnished at a qualified facility , with an exception for interoperative neuromonitoring. A qualified facility must be accredited by an organization specified by the Secretary of Health and Human Services. These accrediting organizations must ensure facilities meet stringent requirements, including maintaining a quality assurance and control program and utilizing specific devices capable of performing both types of electrodiagnostic tests with real-time analysis. Furthermore, individuals performing needle electromyography tests must have completed at least three months of specialized training during an accredited residency or fellowship program, and results must be interpreted on-site and at the time of the procedure. To oversee these changes, the Secretary is directed to establish a National Electrodiagnostic Services Advisory Committee within two years. This committee will provide recommendations on facility requirements, accreditation regulations, and strategies to reduce unnecessary treatments, enhance diagnostic reliability, and address emerging fraud and abuse schemes. Its ultimate goal is to improve the quality of care for Medicare beneficiaries receiving electrodiagnostic services.